VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd.

April 04, 2012 07:00 ET

VentriPoint Diagnostics Enjoys 99.9% Warrant Exercise

SEATTLE, WASHINGTON--(Marketwire - April 4, 2012) - VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (OTCQX:VPTDF) announced today that it has received $682,699 (CDN) as the result of a 99.9% exercise of warrants that expired between the end of this March and the first week of April.

Of 4,707,071 warrants, a total of 4,702,606 were exercised. Approximately 90% of the warrants held an exercise price of $0.15 (CDN) with the remaining at $0.10 (CDN).

The funds will support the Company's ongoing research and development as well as sales and marketing efforts of its 3D heart imaging technology. VentriPoint recently announced that it was the first technology to be approved for Pulmonary Hypertension in Europe. In late March, the Company obtained its listing on the OTCQX, which opened its trading market to U.S. investors. The OTCQX, which includes senior listed companies such as Adidas, BASF and Air France, contributed to volume growth in VentriPoint trading with a combined total of more than five million shares traded in March.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information